

Clinical trials of gene therapy

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
gene therapy vs placebo			
CUPID , 2011 n=25/14 follow-up: 6 months	SERCA2a gene therapy versus placebo	patients NYHA class 3-4 heart failure and an LVEF <35%	Parallel groups double-blind US

More details and results :

- cell-based therapies for heart failure in all types of patients at <http://www.trialresultscenter.org/go-Q515>
- regenerative therapy for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q649>

References

CUPID, 2011:

Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca²⁺-ATPase in Patients With Advanced Heart Failure. Circulation 2011;: [21709064] [10.1161/CIRCULATIONAHA.111.022889](https://doi.org/10.1161/CIRCULATIONAHA.111.022889)

Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, Borow K, Dittrich H, Zsebo KM, Hajjar RJ Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009;15:171-81 [19327618] [10.1016/j.cardfail.2009.01.013](https://doi.org/10.1016/j.cardfail.2009.01.013)

2 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
gene therapy vs placebo			
EUROINJECT-ONE (Gyngysi) , 2005 n=NA follow-up:	percutaneously via NOGA-Myostar injectionsof plasmid encoding plasmid human (ph)VEGF-A(165) versus placebo	patients with chronic myocardial ischemia	double blind

continued...

Trial	Treatments	Patients	Trials design and methods
NCT00090714 <i>ongoing</i> [NCT00090714] n=NA follow-up:	recombinant plasmid DNA [pVGL1(VEGF2)] gene therapy versus placebo	patients with severe Angina Pectoris	Parallel groups double blind

More details and results :

- cell-based therapies for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q300>

References

EUROINJECT-ONE (Gyngysi), 2005:

Gyngysi M, Khorsand A, Zamini S, Sperker W, Strehblow C, Kastrup J, Jorgensen E, Hesse B, Tgil K, Btker HE, Ruzyllo W, Teresiska A, Dudek D, Hubalewska A, Rck A, Nielsen SS, Graf S, Mundigler G, Novak J, Sochor H, Maurer G, Glogar D, Sylven C *Circulation* 2005;112:1157-65 [[16159809](#)] [10.1161/01.CIRCULATION-AHA.105.525782](#)

NCT00090714, :

ongoing trial NCT00090714

↺

Entry terms: Gene Therapy, DNA Therapy, Somatic Gene Therapy,